Axsome Therapeutics Inc (DE:19X)
FRANKFURT:19X
Holding DE:19X?
Track your performance easily

Axsome Therapeutics (19X) Financial Statements

2 Followers

Axsome Therapeutics Financial Overview

Axsome Therapeutics's market cap is currently ―. The company's EPS TTM is €; its P/E ratio is ―; Axsome Therapeutics is scheduled to report earnings on November 4, 2024, and the estimated EPS forecast is €-1.22. See an overview of income statement, balance sheet, and cash flow financials.
Jun 24Mar 24Dec 23Sep 23Jun 23
Income Statement-
Total Revenue$ 87.17M$ 75.00M$ 71.53M$ 57.79M$ 46.70M
Gross Profit$ 79.11M$ 68.70M$ 64.15M$ 51.26M$ 42.10M
EBIT$ -74.48M$ -69.73M$ -98.27M$ -62.12M$ -65.06M
EBITDA$ -71.85M$ -67.27M$ -96.53M$ -60.38M$ -63.47M
Net Income Common Stockholders$ -77.19M$ -68.36M$ -98.65M$ -62.20M$ -67.17M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 315.66M$ 331.44M$ 386.19M$ 416.56M$ 437.11M
Total Assets$ 548.23M$ 545.73M$ 588.24M$ 600.86M$ 611.64M
Total Debt$ 190.60M$ 188.80M$ 186.37M$ 185.57M$ 184.71M
Net Debt$ -125.05M$ -142.64M$ -199.82M$ -230.99M$ -252.40M
Total Liabilities$ 445.37M$ 401.69M$ 397.26M$ 331.35M$ 332.83M
Stockholders Equity$ 102.83M$ 144.04M$ 190.98M$ 269.51M$ 278.82M
Cash Flow-
Free Cash Flow$ -30.16M$ -53.56M$ -30.37M$ -53.92M$ -55.48M
Operating Cash Flow$ -30.11M$ -53.47M$ -30.36M$ -53.55M$ -55.35M
Investing Cash Flow$ -52.00K$ -98.00K$ -7.00K$ -371.00K$ -133.00K
Financing Cash Flow$ 14.38M$ -1.19M$ -2.00K$ 33.37M$ 246.08M
Currency in USD

Axsome Therapeutics Earnings and Revenue History

Axsome Therapeutics Debt to Assets

Axsome Therapeutics Cash Flow

Axsome Therapeutics Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis